chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Next day on Saturday; developed fatigue & extreme tiredness. Slept most of the day. Did eat two meals with a slight headache. Sunday headaches worsened with ear aches, fatigue & slept all day. Gave Patient Tylenol, pushed fluids to tolerance & used cold compress towels on his head for his headaches.  Monday symptoms persisted & taken to his primary MD & was given medication (Tylenol) & was instructed to administer Ibuprofen if symptoms of headache continue. Prior to MD visit he fainted & vomited attempting to use the toilet. Unable to tolerate any light from the house with sensitivity to his vision. Encouraged to hydrate with GatorAid & fluids with meals to tolerance. Was instructed to take patient to Emergency if symptoms persist till Tuesday to obtain IV hydration. Tuesday late afternoon 4:30 pm, took patient to Emergency & was assessed for blood work which was normal & given IV hydration while there. Wednesday- symptoms subsiding with no further headaches & is now able to walk by himself with improving strength. He ate 3 meals today & hydrating most of the day. Sitting up more & trying to improve his strength & endurance. Less sensitive to light.
Pt found out she was pregnant on June 9, 1999. Follow up was received from a physician. LMP was April 25, 1999 and September 20, 1999 revealed normal results. A amniocentesis on Aug 25, 1999 was normal. Maternal serum alpha fetoprotein test was normal. The pt experienced sinusitis during the pregnancy. On 2/05/2000 at 39 weeks gestation the pt gave birth to a normal healthy male.
Information has been received from a health professional concerning a 13 year old female who on 14-AUG-2007 was vaccinated SC with a dose of varicella virus vaccine live (Oka/Merck) (Lot 657941/0851U). It was reported that on 15-AUG-2007, the patient developed an injection site redness that was "size of dollar bill". Additional information has been requested.
Information has been received from a physician concerning a female who on an unspecified date was vaccinated with a dose of GARDASIL vaccine. The physician reported that the patient experienced pruritus and itchiness after receiving GARDASIL vaccine. The patient sought unspecified medical attention. Additional information has been requested. This is in follow-up to report(s) previously submitted on 7/8/2008; 11/3/2008; 11/10/2008. Initial and follow-up information has been received from a physician and a registered nurse concerning a 21 year old female who on 16-NOV-2007 was vaccinated with the first dose of GARDASIL, Lot # 659437/1266U, 0.5 ml, intramuscularly. On 18-JAN-2008, the patient was vaccinated with the second dose of GARDASIL, Lot # 659653/1448U, 0.5 mL, intramuscularly. The physician reported that the patient experienced pruritus and itchiness after receiving GARDASIL. In follow-up information the registered nurse reported that the patient complained of itching (generalized) 2-4 weeks after first injection. It was reported that the patient stated itching occurred more with perspiration or when she got wet. There were no rash or redness detected. It was reported the the patient stated that she was tried BENADRYL and allergy medication but did not help. It was reported that the physician prescribed VISTARIL for a few weeks and disclosed not working. The physician also prescribed METHYLPREDNISOLONE, 4 mg (6 day dose pack). Registered nurse also reported that the patient was pregnant (LMP not reported). It was reported by the registered nurse that since last injection on 19-JAN-2008, patient stated itching has improved. The reporter felt that the generalized itching was other important medical event. Follow-up information was received from the registered nurse who confirmed that the patient was not pregnant at the time of reported adverse event. The registered nurse reported that the patient was still experiencing some itching which appeared to be more noticable and wet. The only medication that the patient was currently taking was a vitamin supplement, METANX, dosage unknown. The patient controlled the itching initially with VISTARIL and never actually took the METHYLPREDNISOLONE. The patient was never and at the time of the report was not incapacitated or disabled but was functioning normally with some persistent itching especially when wet. Follow-up information was received from the physician who confirmed that the patient wasnot pregnant and she had pruritus after receiving the first dose of GARDASIL. No furthere information is available.
Night chills, icy feet, nausea and vomiting, restlessness (jittery), headache: all symptoms except the icy feet abated within 24 hours. Icy feet:  symptom persisted for 4 days, especially in the toes with particular icy feeling in both big toes.
Severe muscle pain and cramping started 2 weeks after vaccine.  Initial symptoms in L neck and L arm, then became more diffuse muscle cramping occurring on a nightly basis.
15mins p/inj pt became diaphoretic, plae & felt faint;this lasted 10-15mins pulse 60, BP 100/60-pt rested w/cold cloth then returned to class;By evening pt's arm was swollen 4-6" arout site & warm to touch; took APAP swelling lasted 5-6days
trouble breathing all day after first vaccine, shortness of breath; strange flavor in her mouth; pain in her left hand/pain in both legs; very tired; Also puffiness and redness after vaccine; Also puffiness and redness after vaccine; This is a spontaneous report from a contactable consumer reported for herself. A 6-decade-old female patient received first dose of bnt162b2 (Pfizer Covid-19 vaccine, Solution for injection, Batch/lot number: Unknown, Expiry date: Not Supplied), via an unspecified route in the left arm on an unspecified date as a single dose for covid-19 immunization. The patient medical history and concomitant medications were not reported. On an unknown, patient experienced trouble breathing all day after first vaccine, shortness of breath. 15 minutes after the vaccine, she had problems the whole day. She had a very strange flavour in her mouth. She had pain in her leg and her hand. It was her left hand on the side of the injection and both legs. And she had very strange flavour in her mouth for few days after she ate. And also, she was very tired. Also, puffiness and redness after vaccine, injection was already prepared ahead of time, and she doesn't know how long it had been there. With the first vaccine she doesn't have any bottle. It was a lot of people, and it was very crowded. The vaccine was there, it was already there, and she didn't know how long it stood there. She wants to know if it's ok if its prepared ahead of time. She usually sees them pull it out from a bottle, but it was already prepared, and she doesn't know if that's ok. How long was it there. The clinical outcome of the events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
I also got COVID 25 days ago/ got COVID after 2 doses; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (I also got COVID 25 days ago/ got COVID after 2 doses) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In February 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In December 2021, the patient experienced COVID-19 (I also got COVID 25 days ago/ got COVID after 2 doses). At the time of the report, COVID-19 (I also got COVID 25 days ago/ got COVID after 2 doses) outcome was unknown.            No concomitant medications were reported. No treatment details were reported.  Company comment: This is a spontaneous case concerning a patient of unknown demographics with no medical history reported, who experienced the unexpected non-serious of COVID-19 approximately 10 months after the second dose of mRNA-1273 vaccine. The exact details regarding the first and the second dose were not provided, therefore lack of efficacy cannot be determined. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a patient of unknown demographics with no medical history reported, who experienced the unexpected non-serious of COVID-19 approximately 10 months after the second dose of mRNA-1273 vaccine. The exact details regarding the first and the second dose were not provided, therefore lack of efficacy cannot be determined. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Numbness in face--primarily on the left side (under the eyes, on the side of my nose, on my chin and jaw). This lasted for almost three days. Taking Benadryl and Ibuprofen helped.
Developed mild pancreatitis Unsure if related Patient developed mild pancreatitis on 5/28/2021. Had had been taking Ashwaganda supplement, No Etoh. No other risk factors. Unknown if vaccine related This occcurred 2 wks after vaccine. No other cause of pancreatitis identified
Patient developed sinusitis symptoms lasting about a month. She developed a rash with swelling from her elbow to axilla around her injection site that lasted 7-10 days. All symptoms began 24 hrs after her injection. She did not seek any treatment for these symptoms other than a OTC antihistamine.
she got her 1st dose about a year ago, but has not gotten the 2nd dose; This case was reported by a consumer via call center representative and described the occurrence of incomplete course of vaccination in a 62-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included shingrix (1st dose received  0.5ml, intramuscularly, in left arm one year prior to the reporting date).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 05-MAY-2022 Reporter's comment: Caller was the patient and stated that she had not gotten the second vaccine but intends to get it. The reporter did not consent to follow up. Additional supportive information: Till the time of reporting, the patient did not receive the 2nd dose, which led to incomplete course of vaccination.
5 min after dose admin c/o of cheeks feeling funny, L eye puffy. HR 138, BP 140/80, pulse ox 98%. A/o & talking w/friend. Over the course of 30 min cheeks feeling improved but felt that cheeks remained a bit numb.  L eye puffiness gone.  Left amb after 45 min  HR 96,  BP 112/70,  pulse ox 99%.
Information has been received from a Registered Nurse, for the Pregnancy Registry for GARDASIL vaccine concerning a 24 year female with of asthma and drug allergic to penicillin, in AUG-2007 motor vehicle accident resulting in multiple fractures, left arm, left leg, right arm; liver and kidney damage; a splenectomy at the time of vaccination, discontinued all medications related to MVA prior to 12 weeks pregnant (PREVACID, NEXIUM), AMBIEN, SEROQUEL, CELEBREX, PROZAC), who on 22-OCT-2007 was vaccinated with the first dose of GARDASIL vaccine (lot# 655154/12100), 0.5ml intramuscular right deltoid, on 12-DEC-2007 was vaccinated the second dose of GARDASIL vaccine (lot#655327/1287U), 0.5ml intramuscular right deltoid. Concomitant therapy included VENTOLIN, fluticasone propionate (+) ADVAIR; prenatal vitamins (unspecified) daily. On 28-FEB-2008 the patient experienced the last menstrual period, and the estimated delivery date was on05-DEC-2008. On 01-APR-2008, the patient serum beta human chorionic gonadotropin test (B HCG; was positive. The patient was reported as a gravida 1, paro 0 (no pregnancies). On 07-APR-2008, the patient underwent an untrasound due to bleeding.  The results revealed a single live intrauterine pregnancy (SLIUP) at 5 weeks, 4 days. EDC 04-DEC-2008). On 27-MAY-2008, the patient's 1st trimester screen revealed normal nuchal translucency, at 12 weeks, 6 days. Additional follow-up information had been received from a completed pregnancy questionnaire on 05-JAN-2009: This report concerned a female patient with depression-anxiety and asthma. ETC was 04-DEC-2008. Concomitant therapy included PROZAC, ADAVIR, VENTOLIN, AMBIEN, and iron. During pregnancy, the patient experienced polyhydramnioe and PIH (pregnancy induced hypertension). The patient underwent multiple ultrasounds, non stress testing and PIH labs. PIH labs were normal. In April 1 2009 ADVAIR was discontinued. During delivery, the patient retained placenta-which required manual extraction and O+E. On 17-NOV-2008, 37 3/? weeks from LMP, a normal male infant was born with no congenital anomalies, 7 lbs 4 oz, apgar score 6.7. The patient  experienced postpartum anemia which required transfusion. PROZAC was switched to ZOLOFT postpartum. This is one of several reports from the same source. Additional information has been requested.
Patient with newly diagnosed MS admitted to neurology service 11/16 pm because for about two weeks patient has had numbness of the left upper thigh and left lower abdomen as well as recent history of numbness and clumsiness of right arm post flu shot given on 11/4/05.   There is a distinct cold sensation.  Patient admitted 11/16/05 for steroid therapy for presumed MS flare possibly precipitated by flu shot.
0935 brought to my attention expiration date on Moderna is 9/19/21 vaccine was labeled accurately  , syringe was labeled accurately (Moderna lot # 025C21A exp 9/19) no adverse reaction to report  today is 9/20/21 moderna box pharmacy 30 day label 10-23-21 crossed with pen  and written above is 9/19/21 LVN administered 1st dose to patient at 0911 pharmacist informed  RN manager aware Informed Dr. infectious disease.
Pt received a tetanus injection on 4-29-08, he stated he developed pain and hard nodule in the same arm approx 4 days later then he developed a blotchy rash down both arms and across his chest no itching or irritation noted.
Acute respiratory failure with hypoxia - He diuresed well and was taken  by cardiology. He did not have any lesion to intervene upon. All of his grafts were open. He does have severe AS, and Cardiology will follow up with him as an outpatient to explore possible TAVR. He did have a slight decrease in his EF so he was started on losartan along with his Lasix 20 mg po every day. Discharged. ED visit to hospital admission within 6 weeks of receiving the COVID vaccine.
Diarrhea; cracking neck/pain in neck; Pain in right shoulder; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Diarrhea), NECK PAIN (cracking neck/pain in neck) and ARTHRALGIA (Pain in right shoulder) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced DIARRHOEA (Diarrhea), NECK PAIN (cracking neck/pain in neck) and ARTHRALGIA (Pain in right shoulder). At the time of the report, DIARRHOEA (Diarrhea), NECK PAIN (cracking neck/pain in neck) and ARTHRALGIA (Pain in right shoulder) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       No concomitant drugs were reported. No treatment medications were reported.   This case was linked to MOD-2021-024627 (Dose 2 case) (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 06-Jul-2021: Telephone Contact Report received and event onset dates and outcomes were updated.
Intense, sudden fatigue; dizziness when standing; shortness of breath after walking only a few feet; unable to lift heavy objects
Pt recvd vax JUL91 & 3 days p/vax pt devel numbness & weakness in hands; also unsteady on feet; No further detials were provided;
02/18/23 presents to ED for "dizziness, nausea and diarrhea". PMHx of "right eye blindness, partial vision loss of left eye, CHI, CKD stage 2, T2DM, GERD, HTN, HLD, CAD, PVD, OSA, Pulmonary hypertension, anemia of chronic disease"
Dizziness, Nausea Vomiting, chills, shortness of breath, weakness. Symptoms lasted until 1/9, except on 1/11, still feels some SOB.
Erythema and warm. Anterior part of Left thigh about 5x7cm. Left inguinal lymph node.
Patient was admitted to local Hospital on 1/30/22 for COVID-19 pneumonia. This is considered a breakthrough case.
PATIENT RECEIVED VACCINE THAT EXPERIENCED A TEMPERATURE EXCURSION, VACCINE WAS KEPT IN THE REFRIGERATOR FOR MORE THAN 30 DAYS. PATIENT REPORTED SORE ARM AFTER 1ST VACCINATION.
Symptom onset was 03/28/2023: cough, congestion, fatigue, headache, muscle aches, runny nose and sore throat. Became weak, fell at home and was transported by ambulance to the hospital on 03/31/2023.
rash all over me/rash covered my upper legs, hips, lower back, upper arms on the inside, and tummy; I was so dizzy that I was walking sideways; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of DIZZINESS (I was so dizzy that I was walking sideways) and RASH (rash all over me/rash covered my upper legs, hips, lower back, upper arms on the inside, and tummy) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029620A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Jan-2020, the patient experienced DIZZINESS (I was so dizzy that I was walking sideways). On 25-Jan-2021, the patient experienced RASH (rash all over me/rash covered my upper legs, hips, lower back, upper arms on the inside, and tummy). At the time of the report, DIZZINESS (I was so dizzy that I was walking sideways) and RASH (rash all over me/rash covered my upper legs, hips, lower back, upper arms on the inside, and tummy) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. Patient reported no treatment, but she has been taking aspirin and a sleeping pill (no drug name provided) to get through it.  24-Jun-2021 - Telephone Contact Report stated that the patient is feeling completely well, she doesn't have symptoms anymore, and would like to have the second shot.   Most recent FOLLOW-UP information incorporated above includes: On 21-Apr-2021: Patient not administered 2nd dose On 24-Jun-2021: Follow-up information received on 24-Jun-2021: Outcome of events updated.
redness on the skin; This is a spontaneous report received from a Pfizer- sponsored program. A contactable consumer (patient) reported for herself that she received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection) via an unspecified route of administration on 02Mar2021 as single dose for covid-19 immunisation, second dose on 23Mar2021 for covid-19 immunisation. Patient's medical history and concomitant medications were not reported. Patient had her 1st dose on 02Mar2021 and experienced mild reactions like redness on the skin. She received the 2nd dose on 23Mar2021 and she thinks that she did not receive the full dose because she felt the vaccine shot drip down on her skin and she mentioned after the 2nd dose, she experienced no adverse events at all. She wants to know if it's okay. The outcome of event was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Initial information received from a healthcare professional on 23 March 2014. A 62-year-old female patient whose medical history and concomitant medications were not reported had received dose of FLUZONE ID (Lot number, expiration date was not reported) in the deltoid left on 31 January 2014. It was reported the patient had hard induration, size of a dime that was red at injection site since time of injection, and no pain was noted at site. The laboratory details and corrective treatment were not reported. At the time of this report the outcome of the adverse event was not resolved. Documents held by sender: none.
For the first week or so, it was just very sore.  Some days the pain would wake me up from a deep sleep.  It changed colors from red to purple to blue to blackish to red again.  It was super itchy for about the first ten days...very hot and red.  It felt like there was a ball in my arm.  Now there is a "mushy" area where the initial injection was done, and then a bruise, and then a brighter red ring around it.  It is no longer itchy and only slightly painful.
Head cold; swollen, red, and hot injection site; swollen, red, and hot injection site; swollen, red, and hot injection site; golf ball sized knot developed at the injection site; Body aches; Chills; This case was reported by a other health professional via call center representative and described the occurrence of injection site swelling in a 27-year-old female patient who received Flu Seasonal QIV Dresden (Fluarix Quadrivalent 2019-2020 season) (batch number ZZ772, expiry date 30th June 2020) for prophylaxis.   On 26th November 2019, the patient received Fluarix Quadrivalent 2019-2020 season (intramuscular) .5 ml. On an unknown date, less than 3 months after receiving Fluarix Quadrivalent 2019-2020 season, the patient experienced injection site swelling, injection site erythema, injection site warmth, injection site mass, general body pain, chills and head cold. On an unknown date, the outcome of the injection site swelling, injection site erythema, injection site warmth, injection site mass, general body pain, chills and head cold were resolved with sequelae.   It was unknown if the reporter considered the injection site swelling, injection site erythema, injection site warmth, injection site mass, general body pain, chills and head cold to be related to Fluarix Quadrivalent 2019-2020 season.  Additional details were reported as follows: The reporter had a patient that reports having a swollen, red, and hot injection site after having the Fluarix vaccine.   A golf ball sized knot developed at the injection site.   All injection site symptoms resolved after one week.   The patient also developed body aches and chills that lasted for three days.   After that she developed a head cold.
pt recv vax & did not remember that recv 1st dose in JAN95 & 12OCT95 pt devel a red, swollen & warm arm @ the inj site;tx w/meds & ice;pt better w/in 24h of tx & recovered;
This spontaneous report as received from a physician via company representative, refers to a 11 year old male patient. On 11-JUL-2013 the patient was vaccinated with the first dose of GARDASIL (lot # J003727, expiration date 07-NOV-2015) (reported as 07-JAN-2015) in the right arm (dose and route of administration were not reported). On the same day (11-JUL-2013) the patient was vaccinated with MENACTRA in the right arm (dose, route and lot number not reported), and TDAP in the left arm. On 11-JUL-2013 the patient developed swelling at the injection site after receiving GARDASIL. On 12-JUL-2013 (reported as the next day), the patient developed blisters around the injection site that lasted "around 3-4 days". The patients was not treated for the events. The patient's mother called the physician office on 18-SEP-2013 to schedule the second dose of GARDASIL. The patient recovered from blisters around the injection site in July 2013 (lasted "around 3-4 days"). The patient recovered from swelling at the injection site on an unknown date in 2013. The relatedness between the events and GARDASIL was not reported. Additional information has been requested.